Affordability and Price Increases of New Cancer Drugs in Clinical Guidelines, 2007–2016

In response to the rising cost of cancer drugs, the National Comprehensive Cancer Network (NCCN) recently developed a value framework, known as “Evidence Blocks,” to grade the efficacy, safety, evidence quality, evidence consistency, and affordability of treatments included in its clinical guideline...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Thomas J, Kesselheim, Aaron S, Gyawali, Bishal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649801/
https://www.ncbi.nlm.nih.gov/pubmed/31360849
http://dx.doi.org/10.1093/jncics/pky016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649801/
https://www.ncbi.nlm.nih.gov/pubmed/31360849
http://dx.doi.org/10.1093/jncics/pky016

Ejemplares similares